Drug intelligence / Profile preview

NeuroTears

Development stage: Preclinical
Lead developer: Genetic Disease Investigators
Administration: Oral

Overview

**NeuroTears** is a patented oral dietary supplement developed by Genetic Disease Investigators for chronic dry eye and neurological dry eye disease. It is marketed to support normal tear production through parasympathetic signaling, with stated support of lacrimal nerves involved in tear secretion and vagus-nerve-mediated inflammatory balance. The product is described as supporting acetylcholine activity rather than as a conventional topical ophthalmic drug. NeuroTears has been evaluated in the registered Neurological Dry Eye Study Stimulating Both Lacrimal and Vagus Nerves, NCT06271005. ([neurotears.com](https://neurotears.com/))

Brand names: NeuroTears
Other names: Neuro Tears

Beyond the preview

Go deeper on NeuroTears.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroTears.

Explore the full profile